ArticleBMJ open2022
COVID-19 vaccination effectiveness rates by week and sources of bias: a retrospective cohort study.
Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Observational methods for COVID-19 vaccine effectiveness research: an empirical evaluation and target trial emulation.International journal of epidemiology · 2024Trial
- Pre-existing Comorbidities as Potential Risk Modifiers for New-Onset Myocarditis and Pericarditis following mRNA COVID-19 Vaccination in Males Aged 18-30 in the United States: A Disproportionality Analysis using VAERS Spontaneous Reporting Data.Drugs - real world outcomes · 2026Article
- Impact of unequal testing on vaccine effectiveness estimates across two study designs: a simulation study.Nature communications · 2025Article
- Effectiveness over time of a primary series of the original monovalent COVID-19 vaccines in adults in the United States.PloS one · 2025Article
- Balancing the efforts of chart review and gains in PRS prediction accuracy: An empirical study.Journal of biomedical informatics · 2024Article
- Effectiveness of BNT162b2 COVID-19 primary series vaccination in children aged 5-17 years in the United States: a cohort study.BMC pediatrics · 2024Article
- The impact of underreported infections on vaccine effectiveness estimates derived from retrospective cohort studies.International journal of epidemiology · 2024Article
- Effectiveness of monovalent COVID-19 booster/additional vaccine doses in the United States.Vaccine: X · 2024Article
- Biases in COVID-19 vaccine effectiveness studies using cohort design.Frontiers in medicine · 2024Review
- Article
- Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study.BMJ (Clinical research ed.) · 2022Article
Corrections and comments
- Update of
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo examine COVID-19 vaccine effectiveness over six 7-day intervals after the first dose and assess underlying bias in observational data. DESIGN AND
settingRetrospective cohort study using Columbia University Irving Medical Center data linked to state and city immunisation registries. OUTCOMES AND MEASURES: We used large-scale propensity score matching with up to 54 987 covariates, fitted Cox proportional hazards models and constructed Kaplan-Meier plots for two main outcomes (COVID-19 infection and COVID-19-associated hospitalisation). We conducted manual chart review of cases in week 1 in both groups along with a set of secondary analyses for other index date, outcome and population choices.
resultsThe study included 179 666 patients. We observed increasing effectiveness after the first dose of mRNA vaccines with week 6 effectiveness approximating 84% (95% CI 72% to 91%) for COVID-19 infection and 86% (95% CI 69% to 95%) for COVID-19-associated hospitalisation. When analysing unexpectedly high effectiveness in week 1, chart review revealed that vaccinated patients are less likely to seek care after vaccination and are more likely to be diagnosed with COVID-19 during the encounters for other conditions. Secondary analyses highlighted potential outcome misclassification for International Classification of Diseases, Tenth Revision, Clinical Modification diagnosis, the influence of excluding patients with prior COVID-19 infection and anchoring in the unexposed group. Long-term vaccine effectiveness in fully vaccinated patients matched the results of the randomised trials.
conclusionsFor vaccine effectiveness studies, observational data need to be scrutinised to ensure compared groups exhibit similar health-seeking behaviour and are equally likely to be captured in the data. While we found that studies may be capable of accurately estimating long-term effectiveness despite bias in early weeks, the early week results should be reported in every study so that we may gain a better understanding of the biases. Given the difference in temporal trends of vaccine exposure and patients' baseline characteristics, indirect comparison of vaccines may produce biased results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.